Agenda

• Factors to consider when designing a therapeutic plan for patients with ER-positive metastatic breast cancer (mBC): prior treatment, disease-free interval, age, menopausal status, symptomatology, location and extent of metastases
• Published research data with and current clinical role of CDK4/6 inhibitors for premenopausal, postmenopausal and elderly patients with ER-positive mBC
• Incidence, monitoring and treatment of commonly occurring toxicities in patients receiving CDK4/6 inhibitors
• Optimal management of disease that progresses on CDK4/6 inhibitors in combination with hormonal therapy
• Incidence and clinical implications of PI3 kinase mutations in progressive ER-positive mBC; recent FDA approval of alpelisib/fulvestrant for patients with PIK3CA mutations whose disease progresses on an endocrine-based regimen
• Spectrum, frequency and severity of toxicities observed with alpelisib; optimal approaches to side-effect management
• Selection of postoperative treatment for patients receiving neoadjuvant chemotherapy with anti-HER2 therapy
• Key efficacy and safety results with adjuvant T-DM1 for patients with HER2-positive primary breast cancer
• Role of pertuzumab as a component of adjuvant anti-HER2 treatment
• Identification of patients with HER2-positive breast cancer for treatment with extended-adjuvant neratinib
• Factors guiding the selection of therapy for patients with progressive HER2-positive mBC
• Similarities and differences between trastuzumab deruxtecan and other antibody-drug conjugates; clinical research findings in HER2-positive mBC
• Mechanism of action of and published efficacy data with tucatinib in combination with trastuzumab/capecitabine
• Recent FDA approvals of neratinib/capecitabine, trastuzumab deruxtecan and tucatinib with trastuzumab/capecitabine for HER2-posItive mBC and optimal integration into practice
• Recognition, prevention and management of toxicities associated with trastuzumab deruxtecan, tucatinib and neratinib
• Biologic rationale for the investigation of immune checkpoint inhibitors in breast cancer
• Available data with anti-PD-1/PD-L1 antibodies for metastatic triple-negative breast cancer (mTNBC)
• Current role of atezolizumab/nab paclitaxel for patients with mTNBC; role of PD-L1 assays
• Emerging Phase III results with pembrolizumab in combination with chemotherapy for mTNBC
• Available data with and potential role of anti-PD-1/PD-L1 antibodies in nonmetastatic TNBC
• Optimal management of immune-mediated adverse events associated with immune checkpoint inhibitors
• Incidence of BRCA1/2 germline and somatic mutations in patients with breast cancer; approach to genetic testing
• Research databases supporting the use of olaparib and talazoparib for patients with mBC and a BRCA germline mutation; patient selection for PARP inhibition and prevention and management of side effects

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

• Apply existing and emerging research data in the diagnostic, therapeutic and supportive care of patients with early and advanced breast cancer.
• Consider available and emerging research evidence to individualize the selection of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
• Implement a long-term clinical plan for the management of HER2-positive metastatic breast cancer (mBC), incorporating existing and investigational targeted treatments.
• Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches to facilitate their introduction into clinical practice for appropriate patients with mBC.
• Appraise published efficacy and safety data with the use of PARP inhibitors in patients with mBC harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings for nonresearch care.
• Recognize the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive mBC.
• Develop an understanding of the frequency of PIK3CA mutations in patients with ER-positive mBC previously treated with endocrine therapy, and appreciate published research data documenting the efficacy and safety of novel agents targeting this abnormality.
• Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer to optimize clinical and quality-of-life outcomes.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/BreastCancer/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Marti and Mr Pizana have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Kaklamani — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc. Dr O’Shaughnessy — Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, GRAIL, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Novartis, Puma Biotechnology Inc and Seattle Genetics.